Entera Bio Ltd. (NASDAQ: ENTX) reported clinical data from its Phase 2 trial of EB613 showing bone mineral density improvements ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE